Merck responds to PHARMAC's article on COX-2 inhibitors.
Woolner
David
D
D001168:Arthritis / Q000188:drug therapy*; D052246:Cyclooxygenase 2 Inhibitors / Q000627:therapeutic use*; D017277:Drug Approval; D004341:Drug Evaluation / Q000379:methods; D004345:Drug Industry; D006801:Humans; D009313:National Health Programs / Q000458:organization & administration; D009520:New Zealand
D052246:Cyclooxygenase 2 Inhibitors